Lantern Pharma Inc. - Common Stock (LTRN)

Lantern Pharma (NASDAQ: LTRN) announced it has scheduled a mid-May 2026 Type C meeting with the U.S. Food and Drug Administration to seek feedback on proposed protocol amendments to its Phase 2 HARMONIC(TM) trial evaluating LP-300 in non-small cell lung cancer. The proposed changes include focusing enrollment on EGFR Exon 21 L858R patients, shifting to a single-arm study design and extending treatment cycles, supported by emerging clinical data showing an 8.3-month median progression-free survival and encouraging response rates in this difficult-to-treat population.

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing Phase 2 HARMONIC™ clinical trial evaluating LP-300. The amendments are grounded in emerging clinical data demonstrating a meaningful and consistent progression-free survival signal in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) who have progressed following any TKI-based treatment (including osimertinib) — a population carrying a particularly poor prognosis and limited remaining therapeutic options. Lantern is seeking the FDA’s scientific guidance to sharpen the trial design around the patients most likely to benefit, and to pursue the most rigorous and efficient development path possible.

ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Biotech Resurgence: Platforms and Pipelines of Today's Innovators investor conference, held April 16, 2026, are now available.

Lantern Pharma (NASDAQ: LTRN) announced the commercial launch of withZeta.ai, its multi-agentic AI co-scientist platform for rare cancer drug discovery, with subscriptions now available across academic and commercial tiers, creating a new non-dilutive revenue stream for the company. The platform, built from Lantern’s RADR (R) oncology-focused AI technologies, will be showcased at a private investor event at Nasdaq MarketSite in New York on April 16, 2026, and demonstrated publicly at the AACR Annual Meeting in San Diego from April 17–22, highlighting its capabilities in accelerating molecular design, clinical development and biomedical research.

Lantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at withzeta.ai, spanning introductory, academic, and commercial tiers, and represent a new, non-dilutive revenue stream for Lantern Pharma shareholders. The platform’s commercial debut will be showcased through two landmark events: a private investor briefing at Nasdaq MarketSite in New York City on April 16, 2026, and public demonstrations at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego at Booth 5054 during April 17–22.

Lantern Pharma (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform’s capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern’s growth roadmap, with participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia.

Lantern Pharma (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform’s capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern’s growth roadmap, with participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia.

ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual investor conference, Biotech Resurgence: Platforms and Pipelines of Today's Innovators, taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. ET.

Lantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on Thursday, April 9, 2026 at 8:30 AM Eastern featuring a live demonstration of withZeta.ai — the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The briefing will be conducted via live webcast and will cover the platform’s capabilities and commercial architecture, the rare cancer market opportunity, competitive positioning, and the Company’s near-term revenue strategy and growth roadmap. Registration is available at: Zoom link https://us06web.zoom.us/webinar/register/1017749924357/WN_o7JaBBCxRDSfEzN6eUCwQA.

Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights led by continued progress in its LP-300 Phase 2 HARMONIC trial, completion of targeted enrollment in Japan, planned protocol discussions with the FDA in mid-May 2026 and advancement of LP-184, LP-284 and STAR-001 across multiple oncology indications. The company said its AI-driven portfolio now targets an estimated annual market opportunity of more than $15 billion, while its RADR(R) platform and newly introduced withZeta.ai multi-agentic co-scientist platform are expanding commercial potential, with beta testing underway at more than 25 biotech companies, cancer research centers and biopharma consultants, as Lantern ended 2025 with approximately $10.1 million in cash, cash equivalents and marketable securities.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the fourth quarter and full year 2025 ended December 31, 2025, and provided an update on its portfolio of AI-driven drug candidates and AI platforms, RADR® and withZeta.ai.

The show also broadcasts across MENA and Latin America as sponsored programming.

Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website.

Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for STAR-001, enabling a planned Phase 1 pediatric clinical trial targeting relapsed or refractory central nervous system malignancies. The study, to be conducted with the POETIC consortium across leading pediatric cancer centers, will evaluate STAR-001 alone and in combination with spironolactone, leveraging the company’s RADR(R) AI platform to target DNA repair mechanisms such as ERCC3, with preclinical data showing significant survival improvements and potential to address critical unmet needs in aggressive pediatric brain cancers.

Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for STAR-001 in a planned Phase 1 pediatric clinical trial (IND No. 179145).

ORLANDO, FL / ACCESS Newswire / March 27, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its AI Investor Conference: From Data Centers to Breakthrough Use Cases, held March 19, 2026, are now available.

Lantern Pharma (NASDAQ: LTRN) will host a webcast to discuss its fourth quarter and fiscal year 2025 operating and financial results on March 30 at 4:30 p.m. Eastern Time. Management, led by President and Chief Executive Officer Panna Sharma, will review results for the period ended Dec. 31, 2025 and provide updates on upcoming milestones, clinical trials and developments related to its RADR (R) AI and machine learning platform.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant

ORLANDO, FL / ACCESS Newswire / March 16, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, announced that Chief Executive Officer and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, taking place Feb. 17–19, 2026, in Boston. During a Day Two presentation on Feb. 19, Mr. Sharma will highlight how the Company’s RADR® AI and machine learning platform supported the development of STAR-001, a brain-penetrant therapeutic candidate, including insights into mechanism of action, biomarker identification, indication selection, and novel combination strategies for aggressive CNS cancers such as glioblastoma and ATRT.